Tali Feferman

Dr. Tali Feferman

orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 January 2015 in Acta Neuropathologica Communications
Verified
Journal Article
Open access
PDF file
MMMarie Maurer
Marie Maurer
SBSylvain Bougoin
Sylvain Bougoin
Tali FefermanTali Feferman
Tali Feferman
MFMélinée Frenkian
Mélinée Frenkian
JBJacky Bismuth
Jacky Bismuth
SBSonia Berrih-Aknin
Sonia Berrih-Aknin
Anti-acetylcholine receptor (AChR) autoantibodies target muscles in spontaneous human myasthenia gravis (MG) and its induced experimental autoimmune model MG (EAMG). The aim of this study was to identify novel functional mechanisms occurring in the muscle pathology of myasthenia. A transcriptome analysis performed on muscle tissue from MG patients (compared with healthy controls) and from EAMG rats (compared with control rats) revealed a deregulation of genes associated with the Interleukin-6 (IL-6) and Insulin-Like Growth Factor 1 (IGF-1) pathways in both humans and rats. The expression of IL-6 and its receptor IL-6R transcripts was found to be altered in muscles of EAMG rats and mice compared with control animals. In muscle biopsies from MG patients, IL-6 protein level was higher than in control muscles. Using cultures of human muscle cells, we evaluated the effects of anti-AChR antibodies on IL-6 production and on the phosphorylation of Protein Kinase B (PKB/Akt). Most MG sera and some monoclonal anti-AChR antibodies induced a significant increase in IL-6 production by human muscle cells. Furthermore, Akt phosphorylation in response to insulin was decreased in the presence of monoclonal anti-AChR antibodies. Anti-AChR antibodies alter IL-6 production by muscle cells, suggesting a putative novel functional mechanism of action for the anti-AChR antibodies. IL-6 is a myokine with known effects on signaling pathways such as Akt/mTOR (mammalian Target of Rapamycin). Since Akt plays a key role in multiple cellular processes, the reduced phosphorylation of Akt by the anti-AChR antibodies may have a significant impact on the muscle fatigability observed in MG patients.

24 November 2021 in Cell Reports
Verified
Journal Article
Open access
IFInbal Farkash
Inbal Farkash
Tali FefermanTali Feferman
Tali Feferman
NCNoy Cohen-Saban
Noy Cohen-Saban
YAYahel Avraham
Yahel Avraham
DMDavid Morgenstern
David Morgenstern
RDRony Dahan
Rony Dahan
Messenger RNA-based vaccines against COVID-19 induce a robust anti-SARS-CoV-2 antibody response with potent viral neutralization activity. Antibody effector functions are determined by their constant region subclasses and by their glycosylation patterns, but their role in vaccine efficacy is unclear. Moreover, whether vaccination induces antibodies similar to those in patients with COVID-19 remains unknown. We analyze BNT162b2 vaccine-induced IgG subclass distribution and Fc glycosylation patterns and their potential to drive effector function via Fcγ receptors and complement pathways. We identify unique and dynamic pro-inflammatory Fc compositions that are distinct from those in patients with COVID-19 and convalescents. Vaccine-induced anti-Spike IgG is characterized by distinct Fab- and Fc-mediated functions between different age groups and in comparison to antibodies generated during natural viral infection. These data highlight the heterogeneity of Fc responses to SARS-CoV-2 infection and vaccination and suggest that they support long-lasting protection differently.

31 March 2023 in Science Immunology
Verified
Journal Article
Closed access
NSNoy Cohen Saban
Noy Cohen Saban
AYAdam Yalin
Adam Yalin
TLTomer Landsberger
Tomer Landsberger
RSRan Salomon
Ran Salomon
AAAjjai Alva
Ajjai Alva
RDRony Dahan
Rony Dahan
FDA-approved anti–PD-L1 monoclonal antibodies (mAbs) bear the IgG1 isotype, whose scaffolds are either wild-type (e.g., avelumab) or Fc-mutated and lacking Fcγ receptor (FcγR) engagement (e.g., atezolizumab). It is unknown whether variation in the ability of the IgG1 Fc region to engage FcγRs renders mAbs with superior therapeutic activity. In this study, we used humanized FcγR mice to study the contribution of FcγR signaling to the antitumor activity of human anti–PD-L1 mAbs and to identify an optimal human IgG scaffold for PD-L1 mAbs. We observed similar antitumor efficacy and comparable tumor immune responses in mice treated with anti–PD-L1 mAbs with wild-type and Fc-mutated IgG scaffolds. However, in vivo antitumor activity of the wild-type anti–PD-L1 mAb avelumab was enhanced by combination treatment with an FcγRIIB-blocking antibody, which was co-administered to overcome the suppressor function of FcγRIIB in the tumor microenvironment (TME). We performed Fc glycoengineering to remove the fucose subunit from the Fc-attached glycan of avelumab to enhance its binding to the activating FcγRIIIA. Treatment with the Fc-afucosylated version of avelumab also enhanced antitumor activity and induced stronger antitumor immune responses compared with the parental IgG. The enhanced effect by afucosylated PD-L1 antibody was dependent on neutrophils and associated with decreased frequencies of PD-L1 + myeloid cells and increased infiltration of T cells in the TME. Our data reveal that the current design of FDA-approved anti–PD-L1 mAbs does not optimally harness FcγR pathways and suggest two strategies to enhance FcγR engagement to optimize anti–PD-L1 immunotherapy.

28 June 2019 in Cancer Immunology, Immunotherapy
Verified
Journal Article
Closed access
PDF file
YMYoav Manaster
Yoav Manaster
ZSZohar Shipony
Zohar Shipony
AHAnat Hutzler
Anat Hutzler
MKMasha Kolesnikov
Masha Kolesnikov
CACamila Avivi
Camila Avivi
GSGuy Shakhar
Guy Shakhar

1 October 2009 in Journal of Neuroimmunology
Verified
Journal Article
Closed access
RMRenuka T.R. Menon
Renuka T.R. Menon
Tali FefermanTali Feferman
Tali Feferman
RARevital Aricha
Revital Aricha
MSMiriam C. Souroujon
Miriam C. Souroujon
SFSara Fuchs
Sara Fuchs

3 April 2023
Verified
Other
Open access
SKShelly Kalaora
Shelly Kalaora
YWYochai Wolf
Yochai Wolf
Tali FefermanTali Feferman
Tali Feferman
EBEilon Barnea
Eilon Barnea
EGErez Greenstein
Erez Greenstein
YSYardena Samuels
Yardena Samuels
Supplementary Tables 1, 2, 4, 5, 8, 10, 13, 14, 15